Psychedelics Archives - Page 15 of 68

2 minute read

EXCLUSIVE: Psychedelics Co. Closes $7.5M Financing – Here’s Its Secret To Raising Millions In A Tough Environment

September 1, 12:19 PM

In the bustling heart of Miami, amidst the buzz of the Benzinga Cannabis and Psychedelics Capital Conference, a pivotal conversation ignited a partnership destined to revolutionize the world of wellness.

CSE:PSYC

2 minute read

Mindset Pharma’s $60M Acquisition, Otsuka’s Leap Into Next-Gen Psychiatry Solutions

By Lara Goldstein

August 31, 1:54 PM

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka Pharmaceutical Co. in an all-cash transaction for approximately $60 (CA$80) million.

CYBN

2 minute read

Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss

By Lara Goldstein

August 31, 9:28 AM

Braxia Scientific Corp.

BRAXF

2 minute read

Red Light Holland’s Q1 2024 Performance: Revenue Soars 53% And Solid Cash Balance

By Lara Goldstein

August 29, 3:28 PM

Ontario-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements, management discussion and analysis for the three months ended June 30. The Numbers:

TRUFF

2 minute read

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M

By Lara Goldstein

August 29, 2:31 PM

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million.

CYBN

4 minute read

Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player’s Retreat, Fellini’s LSD Creativity, Surveys, Financing & More

By Lara Goldstein

August 28, 4:07 PM

Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials

ATAI

2 minute read

Cybin’s Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

By Lara Goldstein

August 28, 1:38 PM

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

CYBN

2 minute read

Irwin Naturals Revenue Sluggish In Q2, Net Loss Grows YOY

By Jelena Martinovic

August 28, 9:26 AM

Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) reported its financial results for the second quarter of fiscal 2023, the period ended June 30, revealing a slight year-over-year improvement in revenue - up by 1.5% to $22.1 million.

CSE:IWIN

2 minute read

Funding The Future Of Psychedelics: Cybin Launches Renewed ATM Equity Program Up To $35M

By Lara Goldstein

August 24, 3:49 PM

Psychedelics biotech Cybin Inc. (NYSE: CYBN) announced it has renewed its previously established at-the-market (ATM) equity program allowing the company to gradually issue and sell up to $35 million in common shares to the public through appointed agents Cantor Fitzgerald Canada Corp.

CYBN

2 minute read

GH Research Psychedelics Firm Q2 2023 Repots $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

By Lara Goldstein

August 24, 3:03 PM

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second quarter en

GHRS